Dren Bio is a San Carlos, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Location: United States, California, Redwood City
Employees: 11-50
Total raised: $125M
Founded date: 2019
Investors 8
| Date | Name | Website |
| 27.10.2023 | Jacket Riv... | jacketrive... |
| 10.07.2026 | Aisling Ca... | aislingcap... |
| - | Mission Bi... | missionbio... |
| - | MBC BioLab... | mbcbiolabs... |
| 29.04.2022 | For Good V... | forgoodven... |
| 07.11.2020 | Taiho Vent... | taihoventu... |
| - | HBM Partne... | hbmpartner... |
| - | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.06.2022 | Series B | $65M | - |
| 19.10.2020 | Series A | $60M | - |
Mentions in press and media 18
| Date | Title | Description |
| 24.07.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2026 with key figures for the first three months of the 2026/2027 financial year | Widespread strong performance In the first quarter of the 2026/2027 financial year, HBM Healthcare Investments generated a profit of CHF 238 million. Once again, net assets exceeded the CHF 2 billion mark as at 30 June 2026. The net asset ... |
| 20.03.2025 | Ad hoc announcement pursuant to Art. 53 LRSanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestones | HBM Healthcare Investments (SIX: HBMN) today announced that Dren Bio, a private portfolio company, and Sanofi have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell enga... |
| 20.03.2025 | Sanofi to acquire Dren Bio's immunology unit | Sanofi to acquire Dren Bio's immunology unit By ReutersMarch 20, 20256:42 AM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link A logo of Sanofi is seen at the Sanofi's Doliprane production site in Co... |
| 20.03.2025 | Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline | Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune systemAcquisition underpins path for Sanofi b... |
| 27.07.2024 | The Shifting Landscape of Biopharma and Real Estate in Colorado | In the heart of Colorado, two significant developments are reshaping the landscape of biopharmaceuticals and commercial real estate. The recent acquisition of a former Mile High Labs site by ScanlanKemperBard (SKB) and a strategic collabora... |
| 24.07.2024 | Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer | – Collaboration combines Dren’s targeted cell depletion platform with Novartis research, development and commercial expertise to advance innovative therapies for cancer – – Dren Bio to receive total upfront consideration of $150 million and... |
| 30.10.2023 | Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer | – Dr. Mehta joins Dren Bio from Genentech where he served as Vice President and Head of Business Development, bringing two decades of industry experience spanning drug development, operations and strategic partnering – FOSTER CITY, Calif.–(... |
| 14.06.2022 | Dren Bio Raises $65M in Series B Financing | Dren Bio, a Foster City, CA-based clinical-stage biopharmaceutical company, raised $65M in Series B funding. The round was led by Aisling Capital and HBM Healthcare Investments, with participation from Pfizer, ArrowMark Partners, Revelation... |
| 14.06.2022 | Dren Bio Lands $65M Series B Funding Round | FOSTER CITY, CA, Dren Bio today announced the completion of their $65 million Series B financing. >> Click here for more funding data on Dren Bio >> To export Dren Bio funding data to PDF and Excel, click here Dren Bio to... |
| 14.06.2022 | Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis P... | – Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer – – The financing round was co-led by Aisli... |
Show more